Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 add-on therapy in lupus nephritis
NL-OMON55520Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability through Week 52 and Percent change in proteinuria at Week 24. Planned start Apr 2019; status: withdrawn.
02
Drugs
deucravacitinib
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON55520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55520.